Russell Investments Group Ltd. Has $73.25 Million Holdings in Amgen Inc. (AMGN)
Russell Investments Group Ltd. cut its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 12.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 425,145 shares of the medical research company’s stock after selling 61,378 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.06% of Amgen worth $73,251,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Bank of New York Mellon Corp lifted its holdings in shares of Amgen by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock valued at $1,403,676,000 after acquiring an additional 195,200 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in shares of Amgen by 1.6% during the first quarter. Schwab Charles Investment Management Inc. now owns 2,894,780 shares of the medical research company’s stock valued at $474,947,000 after acquiring an additional 45,403 shares during the period. UBS Asset Management Americas Inc. lifted its holdings in shares of Amgen by 3.1% during the first quarter. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company’s stock valued at $446,250,000 after acquiring an additional 81,362 shares during the period. Swiss National Bank lifted its holdings in shares of Amgen by 26.5% during the first quarter. Swiss National Bank now owns 2,636,008 shares of the medical research company’s stock valued at $432,490,000 after acquiring an additional 551,600 shares during the period. Finally, Ameriprise Financial Inc. lifted its holdings in shares of Amgen by 0.7% during the first quarter. Ameriprise Financial Inc. now owns 1,479,687 shares of the medical research company’s stock valued at $242,555,000 after acquiring an additional 10,109 shares during the period. 78.13% of the stock is owned by institutional investors.
A number of research analysts have issued reports on the company. UBS AG reissued a “neutral” rating and set a $175.00 price objective (up from $174.00) on shares of Amgen in a report on Tuesday, June 13th. Jefferies Group LLC reissued a “buy” rating and set a $195.00 price objective on shares of Amgen in a report on Tuesday, July 11th. BMO Capital Markets reissued a “buy” rating and set a $198.00 price objective (down from $200.00) on shares of Amgen in a report on Monday, May 22nd. Leerink Swann reissued a “market perform” rating and set a $161.00 price objective on shares of Amgen in a report on Thursday, June 22nd. Finally, Cann reissued a “buy” rating and set a $203.00 price objective (up from $189.00) on shares of Amgen in a report on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $186.04.
Amgen Inc. (NASDAQ:AMGN) traded up 0.57% during trading on Wednesday, hitting $177.75. The stock had a trading volume of 813,618 shares. Amgen Inc. has a 52 week low of $133.64 and a 52 week high of $184.21. The company has a 50-day moving average of $173.66 and a 200 day moving average of $168.55. The company has a market cap of $129.70 billion, a price-to-earnings ratio of 16.19 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The company had revenue of $5.81 billion during the quarter, compared to the consensus estimate of $5.67 billion. During the same period last year, the company earned $2.84 earnings per share. The firm’s revenue was up 2.1% compared to the same quarter last year. On average, equities research analysts anticipate that Amgen Inc. will post $12.57 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be given a dividend of $1.15 per share. The ex-dividend date is Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.60%. Amgen’s dividend payout ratio (DPR) is 41.93%.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.